GlassScriptPhysician profile
Michael Linell Isaacson
NPI 1972572097
$4,785.96
in general payments reported to CMS, 2019-2025
33 companies · $32.15 in 2025
The $32.15 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $324 · 2021: $982 · 2022: $1,639 · 2023: $1,209 · 2024: $255 · 2025: $32.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,496.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $703.07 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $642.57 | 2019-2024 | |
| Amgen INC. | $455.39 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $409.60 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.17 | 2020-2024 | Jardiance |
| Abbott Laboratories | $382.44 | 2020-2024 | Aveir, Mitraclip |
| Merck Sharp & Dohme LLC | $292.81 | 2022-2024 | Verquvo |
| Daxor Corporation | $165.07 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $152.92 | 2022-2024 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $148.06 | 2023 | Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $140.95 | 2019-2022 | |
| Novo Nordisk INC | $136.63 | 2023-2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $106.03 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $105.29 | 2019-2024 | Wainua |
| Alnylam Pharmaceuticals INC. | $65.17 | 2022-2023 | Onpattro |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $49.55 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $44.60 | 2019-2022 | |
| Inspire Medical Systems, INC. | $44.48 | 2023 | Inspire |
| Esperion Therapeutics, INC. | $40.87 | 2021-2022 | |
| Cvrx, INC. | $38.62 | 2022-2023 | Barostim Neo System |
| Boston Scientific Corporation | $38.20 | 2020-2022 | |
| Daiichi Sankyo INC. | $37.80 | 2024 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $31.89 | 2023 | Inpefa |
| Angiodynamics, INC. | $27.28 | 2022 | |
| Cordis US Corp. | $23.33 | 2022 | |
| Akcea Therapeutics, INC. | $20.78 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.67 | 2022 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Cook Medical LLC | $14.23 | 2019 | |
| Atricure, INC. | $13.65 | 2022 | |
| Chiesi USA, INC. | $11.98 | 2019 | |
| Teleflex LLC | $11.86 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Isaacson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.